SIGA Technologies, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). This CRADA will [Read more]
The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price contract to Emergent Biodefense Operations Lansing LLC. The Government intends to purchase 9 Million doses [Read more]
Unprecedented levels of immunosuppression in countries like Australia and the US must be considered in planning for the risk of smallpox re-emerging in the world, an expert in infectious diseases from the [Read more]
See what we’re reading this week at Global Biodefense on topics including Lassa fever stressing the healthcare system in Nigeria, development towards vaccines delivered in pill form, and coverage of the Novichok poisoning [Read more]
See what we’re reading this week at Global Biodefense on topics including the dangers of horsepox synthesis, portable biodosimetry systems, and improving vector-borne pathogen surveillance. SELECT AGENTS Horsepox Synthesis: A Case of [Read more]
Bavarian Nordic announced on Feb. 6 the results of a successful Phase 3 clinical trial led by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that demonstrated the safety and [Read more]
See what we’re reading at Global Biodefense on topics including the safest sample prep methods for MALDI-TOF analysis of threat agents, re-evaluating assumptions on monkeypox research, and looking at health security funding [Read more]
The etiological agent responsible for smallpox disease, Variola viridae (VARV) is responsible for the deaths of hundreds of millions of people throughout history. While smallpox disease is eradicated, repositories of VARV remain, [Read more]
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the advanced research and development of medical countermeasures (MCM) as part of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). [Read more]
Bavarian Nordic A/S this week updated investors on its progress for the first three quarters of 2017, highlighting MVA-BN IMVAMUNE® smallpox vaccine orders and progress on their development pipeline. IMVAMUNE is a [Read more]
© 2018 STEMAR MEDIA